ARTICLE
18 October 2014

New Rules Regarding Drug Names

TA
TozziniFreire Advogados

Contributor

TozziniFreire Advogados logo
A leading full-service law firm in Latin America, TozziniFreire provides safe and innovative legal advice in 47 areas of corporate law. With offices in Brazil and NY, the firm features a unique structure based on industry groups and foreign desks with professionals recognized by the market and key legal guides.
The Brazilian National Agency of Sanitary Surveillance has released new rules regarding pharmaceutical names/trademarks.
Brazil Intellectual Property

The Brazilian National Agency of Sanitary Surveillance ("ANVISA") has released new rules regarding pharmaceutical names/trademarks.

According to the new rules, pharmaceutical companies will be allowed to create a family of drugs with a common name (the "base name"). To be included in the family, all drugs must have at least one common pharmaceutical raw material. Each drug in the family will carry the base name and a distinctive name, which must be a non-exclusive name.

A previous rule, which was revoked, established that companies could use names that were similar to other registered names if they had at least 3 different letters. The new rules will not affect, automatically, drug names previously registered with the ANVISA. Nevertheless, the ANVISA may order a name change if it determines after an administrative proceeding that (i) an irregularity has occurred when the name was first registered or (ii) the name could cause confusion among consumers.

Regardless of these new rules, all intellectual property laws dealing with trademarks in Brazil remain in force. Thus, individuals or legal entities may apply for trademark registrations before the Brazilian Patent and Trademark Office. Furthermore, visually perceptible distinctive signs can still be registered as trademarks.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More